z-logo
Premium
Seventy‐two‐hour stability of Taxol ® in 5% dextrose or 0·9% sodium chloride in Viaflo ® , Freeflex ® , Ecoflac ® and Macoflex N ® non‐PVC bags
Author(s) -
Pourroy B.,
Botta C.,
Solas C.,
Lacarelle B.,
Braguer D.
Publication year - 2005
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/j.1365-2710.2005.00669.x
Subject(s) - turbidimetry , paclitaxel , sodium , chromatography , polyvinyl chloride , chemistry , acetone , chloride , solvent , turbidity , ampoule , high performance liquid chromatography , nuclear chemistry , surgery , organic chemistry , medicine , chemotherapy , oceanography , geology
Summary Background and objectives:  Taxol ® (paclitaxel), is an antimicrotubule agent widely prescribed for the treatment of many tumoral diseases. Taxol ® must be used in non‐polyvinyl chloride bags, diluted to concentrations of 0·3–1·2 mg/mL in 5% dextrose or in 0·9% sodium chloride. Under these conditions, Taxol ® is chemically and physically stable for 27 h at 25 °C. The aim of the study was to evaluate the 72‐h stability of Taxol ® under common clinical use conditions. Methods:  Taxol ® was diluted with 5% dextrose and 0·9% sodium chloride to final concentrations of 0·3 and 1·2 mg/mL in four polyolefin bags (Viaflo ® , Freeflex ® , Ecoflac ® and Macoflex N ® ). Taxol ® ‐stability, was assessed by turbidimetry and by high‐performance liquid chromatography using solutions stored in the dark, over 72 h at +4 °C. Results:  No haze, turbidity, or precipitate was observed. Paclitaxel concentration remained above 95% of the initial value whatever the solvent or container used. Conclusion:  Paclitaxel at 0·3 and 1·2 mg/mL in 5% dextrose and in 0·9% sodium chloride is stable in Viaflo ® , Freeflex ® , Ecoflac ® and Macoflex N ® non‐PVC bags for 72 h in the dark at +4 °C. The longer stability should make the use of Taxol ® in clinical practice easier.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here